Key RCTs also support use of ProLBS (a capsule of 109 CFU daily, for 8 or 10 weeks) together with prebiotic FOS supplements (38.5 mg daily) to provide significant decrease in pro-inflammatory, pro-oncogenic TNF-α [48,51], and significant improvement in quality of life of patients with breast-cancer-related lymphedema [46]. Here, FOS is linked to breast carcinoma.